A PHASE I STUDY OF A 4-WEEK COURSE OF SDZ-RAD (RAD) IN QUIESCENT CYCLOSPORINE-PREDNISONE-TREATED RENAL TRANSPLANT RECIPIENTS1,2

Abstract

This study suggests that the shorter half-life of RAD compared to rapamycin may confer the benefits of rapid attainment of steady state and dissipation of effects upon drug cessation. Controlled, multicenter trials are being planned to assess the impact of these features on clinical outcomes.